Compare · LGND vs LLY
LGND vs LLY
Side-by-side comparison of Ligand Pharmaceuticals Incorporated (LGND) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGND and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.08T, about 182.1x LGND ($5.95B).
- Over the past year, LGND is up 77.4% and LLY is up 55.2% - LGND leads by 22.2 points.
- LLY has been more active in the news (12 items in the past 4 weeks vs 7 for LGND).
- LLY has more recent analyst coverage (25 ratings vs 11 for LGND).
- Company
- Ligand Pharmaceuticals Incorporated
- Eli Lilly and Company
- Price
- $299.53+0.30%
- $1151.58-1.65%
- Market cap
- $5.95B
- $1.08T
- 1M return
- +6.76%
- -7.68%
- 1Y return
- +77.39%
- +55.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 12
- Recent ratings
- 11
- 25
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LGND
- Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
- Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
- Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
- Director Zimmermann Martine sold $342,000 worth of shares (1,200 units at $285.00), decreasing direct ownership by 24% to 3,897 units (SEC Form 4)
- CLO & Secretary Reardon Andrew sold $1,430,434 worth of shares (5,000 units at $286.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 36,514 units (SEC Form 4)
- Amendment: Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Financial Statements and Exhibits
- Ligand to Participate in September Investor Conferences
- Chief Financial Officer Espinoza Octavio exercised 31,641 shares at a strike of $56.91 and sold $9,241,229 worth of shares (31,641 units at $292.06) as part of a pre-agreed trading plan (SEC Form 4)
- Director Haas Jason exercised 6,138 shares at a strike of $51.56 and sold $2,090,062 worth of shares (7,138 units at $292.81), decreasing direct ownership by 20% to 3,981 units (SEC Form 4)
Latest LLY
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,957 units (SEC Form 4)
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,012 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,838 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,536 units (SEC Form 4)
- U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
- Eli Lilly upgraded by Berenberg with a new price target
- Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
- EVP, Global Quality Seymour Melissa gifted 29 shares, decreasing direct ownership by 3% to 1,038 units (SEC Form 4)
- Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference